Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Arno Therapeutics, Inc. (OTC: ARNI).

Full DD Report for ARNI

You must become a subscriber to view this report.


Recent News from (OTC: ARNI)

Arno Therapeutics Announces Plans to Dissolve
Arno Therapeutics, Inc. (ARNI), a biopharmaceutical company, today announced that it has sold substantially all of its remaining assets and will be dissolving by the end of this year. Its last remaining assets were the rights to Onapristone, which it recently sold to Context Biopharma, Inc. ...
Source: Business Wire
Date: December, 22 2017 09:10
Arno Therapeutics Announces Plan to Deregister its Common Stock
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced that its Board of Directors has approved a plan for the Company to file a Form 15 with the Securities an...
Source: Business Wire
Date: March, 28 2017 07:30
Tracking George Soros's Portfolio - Q4 2016 Update
This article is part of a series that provides an ongoing analysis of the changes made to George Soros's US stock portfolio on a quarterly basis. It is based on George Soros's regulatory 13F Form filed on 02/14/2017. Please visit our Tracking Soros Fund Management Holdings article for an...
Source: SeekingAlpha
Date: February, 17 2017 08:56
Arno Therapeutics Announces Update to Onapristone Prostate Cancer Development Program
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has concluded not to enroll the remaining 3 patients in the Company’s ongoing P...
Source: Business Wire
Date: January, 04 2017 16:20
Arno Therapeutics Announces Cancellation of Special Meeting of Stockholders
Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has cancelled the special meeting of stockholders scheduled for December 22, 2016. The Com...
Source: Business Wire
Date: December, 21 2016 16:10
Arno Therapeutics Reports Third Quarter 2016 Financial and Business Update
Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended September 30, 2016 and provided an update on recent clinical de...
Source: Business Wire
Date: November, 14 2016 17:00
Arno Therapeutics reports Q2 results
Arno Therapeutics ( OTCQB:ARNI ): Q2 EPS of -$0.05 Press Release More news on: Arno Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: August, 22 2016 17:49
Arno Therapeutics Reports Second Quarter 2016 Financial and Business Update
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended June 30, 2016 and provided an update on recent clinical developm...
Source: Business Wire
Date: August, 22 2016 17:45
Arno Therapeutics to raise $2.8M via direct placement
Arno Therapeutics ( OTCQB:ARNI ) inks agreements with investors, including affiliates of certain directors of the company, for the sale of 7,929,993 units at $0.35. Each unit consists of one share of common stock and one five-year warrant to purchase 1/2 share of common at $0.4375. More ...
Source: SeekingAlpha
Date: August, 16 2016 09:27
Arno Completes $2.8 Million Private Placement
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has completed a private placement of its common stock and common stock purchase warran...
Source: Business Wire
Date: August, 16 2016 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-07-13N/A0.0028N/AN/A0
2018-07-120.003680.00280.003680.0028150,200
2018-07-11N/A0.005N/AN/A0
2018-07-10N/A0.005N/AN/A0
2018-07-090.0050.0050.0050.005100

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-07-05360,200372,70096.6461Short
2018-05-01325325100.0000Short
2018-04-23200,000200,000100.0000Short
2018-04-1921,60030,00072.0000Short
2018-04-1020,23220,232100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARNI.


About Arno Therapeutics, Inc. (OTC: ARNI)

Logo for Arno Therapeutics, Inc. (OTC: ARNI)

Arno is a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics. The company has exclusive worldwide rights to three innovative clinical stage compounds with unique mechanisms of action that have the potential to be first in class products for the treatment of various forms of cancer, including both hematologic malignancies and solid tumors, and other life threatening diseases. The lead compound, onapristone, is an oral, anti progestin currently in a Phase I/II clinical trial for patients with castration resistant prostate cancer.

 

Contact Information

 

 

Current Management

  • Alexander Zukiwski / CEO, Chief Med. Officer
  • Lester Szymanik / Director, Fin.

Current Share Structure

  • Market Cap: $128,309 - 03/09/2018
  • Authorized: 500,000,000 - 09/30/2016
  • Issue and Outstanding: 49,349,749 - 11/09/2016
  • Float: 14,000,000 - 09/30/2016

 


Recent Filings from (OTC: ARNI)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 03 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 31 2017
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 31 2017
Certification of termination of registration of a class of security under Section 12(g) or notice of suspension of duty to file reports under Section 13 and 15(d) of the Act Section 12 (g).
Filing Type: 15-12GFiling Source: edgar
Filing Date: March, 30 2017
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: March, 28 2017
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: March, 28 2017
Post-effective amendment to an S-8 filing
Filing Type: S-8 POSFiling Source: edgar
Filing Date: March, 28 2017
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2017
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2017
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2017

 

 


Daily Technical Chart for (OTC: ARNI)

Daily Technical Chart for (OTC: ARNI)


Stay tuned for daily updates and more on (OTC: ARNI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ARNI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARNI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ARNI and does not buy, sell, or trade any shares of ARNI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/